Background: At the end of the 19th century, Sir George Thomas Beatson first discovered the positive influence of a bilateral oophorectomy on the development of breast cancer lesions in women with advanced disease. Since then, endocrine therapy has been a key component of the treatment of both early (EBC) and advanced-stage (MBC) hormone receptor (HR)-positive breast cancer. Summary: This review discusses the evolution of this therapeutic approach from the introduction of high-dose estrogen therapy leading to the development of several antiestrogen therapies. Recently, the new generation of drugs includes selective estrogen receptor modulators, orally administered selective estrogen receptor degraders (SERDs), as well as more unique agents such as complete estrogen receptor antagonists, proteolysis targeting chimeric, and selective estrogen receptor covalent antagonists. These drugs are under evaluation in various levels of randomized clinical trials (RCTs) being evaluated in both early and metastatic settings. As of today, the options in EBC are ranging from short-term neoadjuvant endocrine therapy to monitor the responsiveness of Ki-67 to combined endocrine therapy in MBC, introducing the combination of endocrine therapy and CDK4/6 inhibition as well as PARP inhibition in patients with luminal breast cancer presenting with germline BRCA1/2 mutations. The results of global RCTs are settled in global and local guidelines to optimize the individual therapy of our patients with luminal EBC. Key Messages: Endocrine intervention in hormone-sensitive breast cancer remains one of the most important options in all settings of early and metastatic breast cancer.

1.
Beatson
G
.
On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases
.
Lancet
.
1896
;
148
(
3803
):
162
5
.
2.
Ingle
JN
,
Ahmann
DL
,
Green
SJ
,
Edmonson
JH
,
Bisel
HF
,
Kvols
LK
et al
.
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
.
N Engl J Med
.
1981
;
304
(
1
):
16
21
.
3.
Ellis
MJ
,
Gao
F
,
Dehdashti
F
,
Jeffe
DB
,
Marcom
PK
,
Carey
LA
et al
.
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study
.
JAMA
.
2009
;
302
(
7
):
774
80
.
4.
Heldring
N
,
Pike
A
,
Andersson
S
,
Matthews
J
,
Cheng
G
et al
.
Estrogen receptors: how do they signal and what are their targets
.
Physiol Rev
.
2007
;
87
(
3
):
905
31
.
5.
Allison
KH
,
Hammond
MEH
,
Dowsett
M
,
McKernin
SE
,
Carey
LA
,
Fitzgibbons
PL
et al
.
Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology/college of American pathologists guideline update
.
Arch Pathol Lab Med
.
2020
;
144
(
5
):
545
63
.
6.
Thill
M
,
Kolberg-Liedtke
C
,
Albert
US
,
Banys-Paluchowski
M
,
Bauerfeind
I
,
Blohmer
JU
et al
.
AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2023
.
Breast Care
.
2023
;
18
(
4
):
305
14
.
7.
Park-Simon
TW
,
Müller
V
,
Jackisch
C
,
Albert
US
,
Banys-Paluchowski
M
,
Bauerfeind
I
et al
.
AGO recommendations for the diagnosis and treatment of patients with early breast cancer (EBC): update 2023
.
Breast Care
.
2023
18
4
).
8.
Burstein
HJ
,
Somerfield
MR
,
Barton
DL
,
Dorris
A
,
Fallowfield
LJ
,
Jain
D
et al
.
Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update
.
J Clin Oncol
.
2021
;
39
(
35
):
3959
77
.
9.
Johnston
SRD
,
Toi
M
,
O’Shaughnessy
J
,
Rastogi
P
,
Campone
M
,
Neven
P
et al
.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
.
Lancet Oncol
.
2023
;
24
(
1
):
77
90
.
10.
Slamon
DJ
,
Stroyakovskiy
D
,
Yardley
DA
,
Huang
CS
,
Fasching
PA
,
Crown
J
et al
.
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2: early breast cancer–primary results from the Phase III NATALEE trial
.
J Clin Oncol
.
2023
41
Suppl 16
LBA500
.
11.
Jensen
EV
.
On the mechanism of estrogen action
.
Perspect Biol Med
.
1962
;
6
:
47
54
.
12.
Harper
MJK
,
Walpole
AL
.
A new derivative of triphenylethylene: effect on implantation and mode of action in rats
.
J Reprod Fertil
.
1967
;
13
(
1
):
101
19
.
13.
Early Breast Cancer Trialists’ Collaborative Group EBCTCG
Davies
C
,
Godwin
J
,
Gray
R
,
Clarke
M
,
Cutter
D
et al
.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
.
Lancet
.
2011
;
378
(
9793
):
771
84
.
14.
Davies
C
,
Pan
H
,
Godwin
J
,
Gray
R
,
Arriagada
R
,
Raina
V
et al
.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
.
Lancet
.
2013
;
381
(
9869
):
805
16
.
15.
Gray
RG
,
Rea
D
,
Handley
K
,
Bowden
SJ
,
Perry
P
,
Earl
HM
et al
.
aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer
.
J Clin Oncol
.
2013
31
15 Suppl l
5
.
16.
Santen
RJ
,
Brodie
H
,
Simpson
ER
,
Siiteri
PK
,
Brodie
A
.
History of aromatase: saga of an important biological mediator and therapeutic target
.
Endocr Rev
.
2009
;
30
(
4
):
343
75
.
17.
Rugo
HS
,
Rumble
RB
,
Macrae
E
,
Barton
DL
,
Connolly
HK
,
Dickler
MN
et al
.
Endocrine therapy for hormone receptor: positive metastatic breast cancer–American society of clinical oncology guideline
.
J Clin Oncol
.
2016
;
34
(
25
):
3069
103
.
18.
NCCN guidelines version 4.2023 breast cancer
. Available from: www.nccn.org.
19.
Early Breast Cancer Trialists’ Collaborative Group EBCTCG
.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
.
Lancet
.
2015
;
386
(
10001
):
1341
52
.
20.
Burstein
HJ
,
Lacchetti
C
,
Anderson
H
,
Buchholz
T
,
Davidson
NE
,
Gelmon
KA
et al
.
Adjuvant endocrine therapy for women with hormone receptor: positive breast cancer–ASCO clinical practice guideline focused update
.
J Clin Oncol
.
2019
;
37
(
5
):
423
38
.
21.
Gray
R
.
Abstract GS3-03: effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality—an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
.
Cancer Res
.
2019
79
4 Suppl
GS3-03
.
22.
Early Breast Cancer Trialists’ Collaborative Group EBCTCG
.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
.
Lancet
.
2005
;
365
(
9472
):
1687
717
.
23.
Davidson
NE
,
O’Neill
AM
,
Vukov
AM
,
Osborne
CK
,
Martino
S
,
White
DR
et al
.
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor positive breast cancer: results from INT 0101 (E5188)
.
J Clin Oncol
.
2005
;
23
(
25
):
5973
82
.
24.
Francis
PA
,
Pagani
O
,
Fleming
GF
,
Walley
BA
,
Colleoni
M
,
Láng
I
et al
.
Tailoring adjuvant endocrine therapy for premenopausal breast cancer
.
N Engl J Med
.
2018
;
379
(
2
):
122
37
.
25.
Francis
PA
,
Fleming
GF
,
Láng
I
,
Ciruelos
EM
,
Bonnefoi
HR
,
Bellet
M
et al
.
Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT
.
J Clin Oncol
.
2023
;
41
(
7
):
1370
5
.
26.
Pagani
O
,
Walley
BA
,
Fleming
GF
,
Colleoni
M
,
Láng
I
,
Gomez
HL
et al
.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials
.
J Clin Oncol
.
2023 Mar 1
41
7
1376
82
.
27.
Early Breast Cancer Trialists’ Collaborative Group EBCTCG
.
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7,030 women from four randomised trials
.
Lancet Oncol
.
2022
;
23
(
3
):
382
92
.
28.
Ribi
K
,
Luo
W
,
Bernhard
J
,
Francis
PA
,
Burstein
HJ
,
Ciruelos
E
et al
.
Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial
.
J Clin Oncol
.
2016
;
34
(
14
):
1601
10
.
29.
Loibl
S
,
Marme
F
,
Martin
M
,
Untch
M
,
Bonnefoi
H
,
Kim
SB
et al
.
Palbociclib for residual high-risk Invasive HR-positive and HER2-negative early breast cancer: the Penelope-B trial
.
J Clin Oncol
.
2021
;
39
(
14
):
1518
30
.
30.
Gnant
M
,
Dueck
AC
,
Frantal
S
,
Martin
M
,
Burstein
HJ
,
Greil
R
et al
.
Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03)
.
J Clin Oncol
.
2022
;
40
(
3
):
282
93
.
31.
Harbeck
N
,
Rastogi
P
,
Martin
M
,
Tolaney
SM
,
Shao
ZM
,
Fasching
PA
et al
.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breastcancer: updated efficacy and Ki-67 analysis from the MonarchE study
.
Ann Oncol
.
2021
;
32
(
12
):
1571
81
.
32.
Nitz
UA
,
Gluz
O
,
Kümmel
S
,
Christgen
M
,
Braun
M
,
Aktas
B
et al
.
Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2– early breast cancer
.
J Clin Oncol
.
2022
;
40
(
23
):
2557
67
.
33.
Harbeck
N
Discussant of LBA at ASCO 2023
.
34.
Patel
R
,
Klein
P
,
Tiersten
A
,
Sparano
JA
.
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
.
NPJ Breast Cancer
.
2023
;
9
(
1
):
20
.
35.
Prat
A
,
Saura
C
,
Pascual
T
,
Hernando
C
,
Munoz
M
,
Pare
L
et al
.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
.
Lancet Oncol
.
2020
;
21
(
1
):
33
43
.
36.
Hurvitz
SA
,
Martin
M
,
Press
MF
,
Chan
D
,
Fernandez-Abad
M
,
Petru
E
et al
.
Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+/HER2- breast cancer
.
Clin Cancer Res
.
2020
;
26
(
3
):
566
80
.
37.
Cottu
P
,
D’Hondt
V
,
Dureau
S
,
Lerebours
F
,
Desmoulins
I
,
Heudel
P
et al
.
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
.
Ann Oncol
.
2018
;
29
(
12
):
2334
40
.
38.
Ma
CX
,
Gao
F
,
Luo
J
,
Northfelt
DW
,
Goetz
M
,
Forero
A
et al
.
NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer
.
Clin Cancer Res
.
2017
;
23
(
15
):
4055
65
.
39.
Saura
C
,
Hlauschek
D
,
Oliveira
M
,
Zardavas
D
,
Jallitsch-Halper
A
,
de la Peña
L
et al
.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
.
Lancet Oncol
.
2019
;
20
(
9
):
1226
38
.
40.
Mayer
IA
,
Prat
A
,
Egle
D
,
Blau
S
,
Fidalgo
JAP
,
Gnant
M
et al
.
A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB)
.
Clin Cancer Res
.
2019
;
25
(
10
):
2975
87
.
41.
Metzger
O
,
Herold
C
,
Poncet
C
,
De Swert
H
,
Casas-Martin
J
,
Partridge
A
et al
.
Abstract OT1-04-01: AMEERA-6–phase 3 study of adjuvant amcenestrant versus tamoxifen for patients with hormone receptor-positive early breast cancer, who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity
.
Cancer Res
.
2023
83
5 Suppl
OT1-04-1
.
42.
Geyer
E
,
Bardia
A
,
Harbeck
N
,
Rimawi
MF
,
Hurvitz
A
,
Martin
M
et al
.
lidERA Breast Cancer (BC): phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)
.
J Clin Oncol
.
2022
40
Suppl 16
TPS616
.
43.
Tutt
AN
,
Garber
JE
,
Kaufman
B
,
Viale
G
,
Fumagalli
D
,
Rastogi
P
et al
.
Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
.
N Engl J Med
.
2021
;
384
(
25
):
2394
405
.
44.
Fasching
PA
,
Bardia
A
,
Quiroga
V
,
Park
YH
,
Blancas
I
,
Alonso
JL
et al
.
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): final analysis of the randomized, open-label, international phase 2 coopERA BC study
.
J Clin Oncol
.
2022
40
16 Suppl l
589
.
45.
Nabiveca
N
,
Fasching
PA
.
Endocrine treatment for breast cancer patients revised-History, Standard of care, and possibilities of improvement
.
Cancer
.
2021
;
13
:
5643
.
You do not currently have access to this content.